Chemify, the deep-tech company specializing in digitizing molecule creation through chemistry, robotics, computation and AI, has launched its first Chemifarm facility in Glasgow's Maryhill district. The 21,500-ft² site represents the world's most advanced laboratory for molecular design and synthesis, combining AI-driven molecular-design capabilities with industrial-scale robotic synthesis to dramatically accelerate the journey from concept to compound. This advancement is expected to significantly impact small-molecule medicine discovery and next-generation materials development for partners addressing complex societal challenges.
At the core of the Chemifarm is the Chemputation platform, featuring a bespoke programming language, extensible robotics, and the world's largest curated library of validated reactions. This integrated system enables the on-demand design, optimization and scale-up of molecules previously considered unreachable. CEO and Founder Lee Cronin described the facility as a watershed moment for molecular innovation, stating that the combination of automation, AI and scalable synthesis allows movement from code to compound faster than ever before.
The £12 million project received support through the https://www.ukri.org/councils/innovate-uk/ Glasgow City Region Innovation Accelerator Programme, a UK Government-led initiative delivered by Innovate UK. Scottish Enterprise also provided a £1.1 million grant for the project. The facility will create 60 new jobs and safeguard over 50 existing roles in Glasgow, Scotland, contributing to regional economic development and strengthening the area's position in advanced chemical and pharmaceutical industries.
The Chemifarm features dedicated production suites, R&D laboratories, engineering and fabrication zones, along with a secure cloud architecture capable of storing petabytes of high-resolution chemical data for AI-powered analysis. The facility will also serve as a prototyping center for next-generation Chemifarm hardware destined for future global sites. This infrastructure supports Chemify's existing partnerships with major pharmaceutical, biotech and materials-science companies, providing confidential, on-demand access to bespoke molecules for early-stage research and development.
University leaders and government officials emphasized the transformative impact of translating academic research into industrial innovation. The facility exemplifies how place-based innovation support can deliver global impact by leveraging regional strengths, further cementing the UK's reputation as a leader in advanced chemical and pharmaceutical industries while positioning Scotland at the forefront of the global healthtech market.
